Vanguard Fiduciary Trust
RLMD icon

Vanguard Fiduciary Trust’s Relmada Therapeutics RLMD Stock Holding History

Vanguard Fiduciary Trust’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.08M Buy
734,191
+284,380
+63% +$1.99M ﹤0.01% 2169
2026
Q1 		$3.13M Buy
+449,811
New +$2.13M ﹤0.01% 2330

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust's RLMD Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Relmada Therapeutics (RLMD) stake by 63% in Q2 2026, buying an estimated $1.99M and bringing the position to 734,191 shares worth $5.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2169.

Vanguard Fiduciary Trust first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Vanguard Fiduciary Trust held 734,191 shares of Relmada Therapeutics worth $5.08M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 284,380 Relmada Therapeutics shares in Q2 2026, an estimated $1.99M.
  • Relmada Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2169 holding.
  • Vanguard Fiduciary Trust first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.